More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Earlier this month, Novartis announced that Joseph Jimenez, current CEO , will step down as CEO in February 2018 and turn the reins over to Vasant Narasimhan, MD, current global head of drug development and chief medical officer at Novartis, who...

Biomanufacturing is a leading area of investment for the pharmaceutical majors. So what are the leading projects announced, underway, or recently completed? DCAT Value Chain Insights (VCI) examines key projects. With recent large investments by...

Kåre Schultz, now president and CEO of H. Lundbeck A/S, has been appointed president and CEO of Teva Pharmaceutical Industries. In taking the helm at Teva, Schultz is taking on the task of increasing sales and further paying down debt at the...

The oncology sector is the largest therapeutic sector in the pharmaceutical industry. So what is in store for the global oncology market? Total spending for oncologics and supportive care worldwide is expected to exceed $147 billion by 2021. With...

Batch processing is the historical and dominant form of manufacturing in the pharmaceutical industry, but continuous manufacturing is beginning to take root. Where does it stand with respect to bioprocessing? Continuous biomanufacturing offers...

Although the future of healthcare reform is unclear, debates on drug pricing continue. So what should be on the radar for the pharmaceutical industry? Drug pricing is a hot topic in Congress' and the Trump Administration’s focus on healthcare...

Precision medicines, defined as a medical approach that proposes to prevent and treat disease based upon a person's unique genetic makeup and lifestyle habits, is touted as the next wave in drug development. So has the promise of precision...